Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Bergenstal

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Diabetes|August 1, 1985
Observations on control of glycemia with conventional insulin therapy or continuous subcutaneous insulin infusionW V Tamborlane, M C Champion, R A Rizza, et al.
Diabetes Care|June 26, 2001
Use of an automated device for alternative site blood glucose monitoringS E Fineberg, R M Bergenstal, R M Bernstein, et al.
Diabetes, Obesity & Metabolism|April 11, 2014
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DMS J Jacober, J Rosenstock, R M Bergenstal, et al.
Diabetes & Metabolism|June 18, 2017
Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trialG B Bolli, M C Riddle, R M Bergenstal, et al.
Diabetes, Obesity & Metabolism|February 3, 2015
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)G B Bolli, M C Riddle, R M Bergenstal, et al.
Diabetes, Obesity & Metabolism|February 11, 2012
Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care settingM Pawaskar, Q Li, B J Hoogwerf, et al.
Diabetes, Obesity & Metabolism|July 15, 2015
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensionH Yki-Järvinen, R M Bergenstal, G B Bolli, et al.
Diabetes|November 1, 1984
Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetesK S Polonsky, K C Herold, J L Gilden, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1984
The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetesR M Bergenstal, R M Cohen, E Lever, et al.
Diabetes, Obesity & Metabolism|June 7, 2016
Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3R M Bergenstal, H Lunt, E Franek, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Diabetes|August 1, 1985
Observations on control of glycemia with conventional insulin therapy or continuous subcutaneous insulin infusionW V Tamborlane, M C Champion, R A Rizza, et al.
Diabetes Care|June 26, 2001
Use of an automated device for alternative site blood glucose monitoringS E Fineberg, R M Bergenstal, R M Bernstein, et al.
Diabetes, Obesity & Metabolism|April 11, 2014
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DMS J Jacober, J Rosenstock, R M Bergenstal, et al.
Diabetes & Metabolism|June 18, 2017
Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trialG B Bolli, M C Riddle, R M Bergenstal, et al.
Diabetes, Obesity & Metabolism|February 3, 2015
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)G B Bolli, M C Riddle, R M Bergenstal, et al.
Diabetes, Obesity & Metabolism|February 11, 2012
Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care settingM Pawaskar, Q Li, B J Hoogwerf, et al.
Diabetes, Obesity & Metabolism|July 15, 2015
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensionH Yki-Järvinen, R M Bergenstal, G B Bolli, et al.
Diabetes|November 1, 1984
Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetesK S Polonsky, K C Herold, J L Gilden, et al.
The Journal of Clinical Endocrinology and Metabolism|June 1, 1984
The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetesR M Bergenstal, R M Cohen, E Lever, et al.
Diabetes, Obesity & Metabolism|June 7, 2016
Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3R M Bergenstal, H Lunt, E Franek, et al.
Pageof 3